Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study.

PURPOSE Controversy exists about whether vaginal estrogens interfere with the efficacy of aromatase inhibitors (AIs) in breast cancer patients. With the greater incidence of vaginal atrophy in patients on AIs, a safe and effective nonestrogen therapy is necessary. We hypothesized that vaginal testosterone cream could safely treat vaginal atrophy in women on AIs. METHODS Twenty-one postmenopausal breast cancer patients on AIs with symptoms of vaginal atrophy were treated with testosterone cream applied to the vaginal epithelium daily for 28 days. Ten women received a dose of 300 μg, 10 received 150 μg, and one was not evaluable. Estradiol levels, testosterone levels, symptoms of vaginal atrophy, and gynecologic examinations with pH and vaginal cytology were compared before and after therapy. RESULTS Estradiol levels remained suppressed after treatment to <8 pg/mL. Mean total symptom scores improved from 2.0 to 0.7 after treatment (p < .001) and remained improved 1 month thereafter (p = .003). Dyspareunia (p = .0014) and vaginal dryness (p <.001) improved. The median vaginal pH decreased from 5.5 to 5.0 (p = .028). The median maturation index rose from 20% to 40% (p < .001). Although improvement in total symptom score was similar for both doses (-1.3 for 300 μg, -0.8 for 150 μg; p = .37), only the 300-μg dose was associated with improved pH and maturation values. CONCLUSIONS A 4-week course of vaginal testosterone was associated with improved signs and symptoms of vaginal atrophy related to AI therapy without increasing estradiol or testosterone levels. Longer-term trials are warranted.

[1]  C. Labrie,et al.  High internal consistency and efficacy of intravaginal DHEA for vaginal atrophy , 2010, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[2]  P. Dubey,et al.  A comparative study of the effects of local estrogen with or without local testosterone on vulvovaginal and sexual dysfunction in postmenopausal women. , 2010, The journal of sexual medicine.

[3]  M. Moasser,et al.  A Phase II Study of Vaginal Testosterone Cream (TEST) vs. Estring for Vaginal Dryness or Decreased Libido in Women with Early Stage Breast Cancer (BC) Treated with Aromatase Inhibitors (AIs). , 2009 .

[4]  C. Labrie,et al.  Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration , 2009, Menopause.

[5]  C. Labrie,et al.  Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women , 2009, Menopause.

[6]  C. Labrie,et al.  Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy , 2009, Menopause.

[7]  R. Wolfe,et al.  The incidence of invasive breast cancer among women prescribed testosterone for low libido. , 2009, The journal of sexual medicine.

[8]  F. Berrino,et al.  Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort , 2009, Cancer Epidemiology Biomarkers & Prevention.

[9]  G. Braunstein,et al.  Testosterone and the breast , 2008, Menopause international.

[10]  C. Rock,et al.  Reproductive Steroid Hormones and Recurrence-Free Survival in Women with a History of Breast Cancer , 2008, Cancer Epidemiology Biomarkers & Prevention.

[11]  Graham A Colditz,et al.  Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women. , 2006, Journal of the National Cancer Institute.

[12]  D. Spiegelman,et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.

[13]  M. Dowsett,et al.  Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Burger Faculty Opinions recommendation of Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. , 2006 .

[15]  T. Marshall,et al.  Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life , 2006, Climacteric : the journal of the International Menopause Society.

[16]  C. Castelo-Branco,et al.  Management of post-menopausal vaginal atrophy and atrophic vaginitis. , 2005, Maturitas.

[17]  G. Braunstein,et al.  Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. , 2005, The Journal of clinical endocrinology and metabolism.

[18]  N. Watts,et al.  Safety and Efficacy of a Testosterone Patch for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women: A Randomized, Placebo-Controlled Trial , 2005 .

[19]  F. Berrino,et al.  Serum testosterone levels and breast cancer recurrence , 2005, International journal of cancer.

[20]  J. Cuzick,et al.  Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. van Limbergen,et al.  Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients , 2004, Anti-cancer drugs.

[22]  S. Davis,et al.  Testosterone effects on the breast: implications for testosterone therapy for women. , 2004, Endocrine reviews.

[23]  L. Speroff Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. , 2003, Obstetrics and gynecology.

[24]  Mitch Dowsett,et al.  Aromatase inhibitors in breast cancer. , 2003, The New England journal of medicine.

[25]  G. Davila,et al.  Are women with urogenital atrophy symptomatic? , 2003, American journal of obstetrics and gynecology.

[26]  R. Santen To block estrogen's synthesis or action: that is the question. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  J. A. van der Laak,et al.  The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. , 2002, Journal of clinical pathology.

[28]  Orman,et al.  Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. , 2000, The New England journal of medicine.

[29]  J. Manson,et al.  Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. , 1998, Journal of the National Cancer Institute.

[30]  B. Pasternack,et al.  Relation of serum levels of testosterone and dehydroepiandrosterone sulfate to risk of breast cancer in postmenopausal women. , 1997, American journal of epidemiology.

[31]  A. Straughn,et al.  Delivery of dehydroepiandrosterone to premenopausal women: effects of micronization and nonoral administration. , 1996, American journal of obstetrics and gynecology.

[32]  M. Notelovitz Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. , 1995, Maturitas.

[33]  M. Dowsett,et al.  ARIMIDEX™: A new oral, once-a-day aromatase inhibitor , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[34]  R. Santen,et al.  Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer , 1995, Cancer.

[35]  M. Gelfand,et al.  Treating Vaginal Dryness in Breast Cancer Patients: Results of Applying a Polycarbophil Moisturizing Gel , 1994 .

[36]  E. Nieschlag,et al.  TRANSDERMAL TESTOSTERONE , 1989, The Lancet.

[37]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.

[38]  J. Hustin,et al.  Cytologic evaluation of the effect of various estrogens given in postmenopause. , 1977, Acta cytologica.

[39]  S. Salinger Proliferative effect of testosterone propionate on human vaginal epithelium. , 1950, Acta endocrinologica.

[40]  F. Wilcoxon Individual Comparisons by Ranking Methods , 1945 .

[41]  W. Steinberg,et al.  17&bgr;‐Estradiol Vaginal Tablet Versus Conjugated Equine Estrogen Vaginal Cream to Relieve Menopausal Atrophic Vaginitis , 2000 .

[42]  A. Dobs,et al.  Transdermal testosterone. Viewpoints , 1998 .

[43]  B. Risberg,et al.  The vaginal epithelium in the postmenopause--cytology, histology and pH as methods of assessment. , 1995, Maturitas.

[44]  L. Nachtigall Comparative study: Replens versus local estrogen in menopausal women. , 1994, Fertility and sterility.

[45]  H. Adlercreutz,et al.  Inhibition of aromatase with CGS 16949A in postmenopausal women. , 1989, The Journal of clinical endocrinology and metabolism.